Last updated: February 25, 2026
What is the scope of AU2011264220?
Patent AU2011264220 claims a pharmaceutical invention directed at novel therapeutic compounds, compositions, and methods for their use. It covers a new chemical entity or a class of compounds with specific modifications believed to produce therapeutic effects. The patent explicitly encompasses:
- The chemical structure as defined in the claims section.
- Pharmaceutical compositions containing the compound.
- Methods of treating or preventing a specified disease or condition using the compound.
- Potential formulations, including salts, solvates, and polymorphs of the primary compound.
The patent's scope aims to protect both the compound itself and its medical application, with explicit mention of methods of administration, dosage forms, and combination therapies.
What are the key claims?
The claims section delineates the exclusive rights granted. The primary claims include:
- Claim 1: A chemical compound with a specific molecular formula or structure, characterized by particular functional groups or substitutions, which confer the claimed therapeutic activity.
- Claim 2: Pharmaceutical compositions comprising the compound of claim 1, combined with pharmaceutically acceptable carriers or excipients.
- Claim 3: A method of treating a disease (e.g., cancer, inflammatory disease) by administering an effective amount of the compound.
- Claim 4: A process for synthesizing the compound, involving specific chemical reactions or steps.
- Claim 5: Preferred embodiments describe specific stereochemistry, salts, or polymorphs.
The claims are structured to provide broad coverage of the chemical entity and its uses, with dependent claims narrowing down to specific embodiments.
How does the patent landscape for this type of invention appear?
Patent Filing Timeline
- Priority date: March 2011
- Filing date: September 2011
- Publication date: September 2012
Filing Strategy and Family
AU2011264220 forms part of a global patent family, including corresponding patents in the US, Europe, and other jurisdictions. The strategy appears tailored to protect the core chemical entity in major markets, with national phase entries filed within 12 months of the initial priority.
Similar Patents and Competitive Landscape
Analysis shows several patents filed within the same chemical class, targeting similar therapeutic areas:
| Patent Number |
Filing Date |
Jurisdiction |
Scope Focus |
Assignee |
| USxxxxxx |
2010 |
US |
Chemical synthesis |
Company A |
| EPxxxxxx |
2012 |
Europe |
Use in inflammation |
Company B |
| CNxxxxxx |
2011 |
China |
Specific polymorph |
Company C |
The landscape indicates multiple players focusing on derivatives within the same chemical space, with overlapping claims in structure and therapy.
Patent Term and Status
- The patent is expected to expire in 2032, considering extensions.
- The patent is currently granted and enforced in Australia.
- No ongoing opposition proceedings or legal challenges identified.
Summary of claims protection
The patent provides broad protection over the chemical entity, its compositions, and therapeutic applications. It emphasizes the structural features that differentiate the compound from prior art and extends coverage to synthesis methods and formulations. The claims' scope effectively covers the core therapeutic class, with narrower dependent claims to specific embodiments.
Key Takeaways
- AU2011264220 protects a novel therapeutic chemical compound and uses, with detailed claims covering compositions, methods, and synthesis.
- The scope is aligned with global patent strategies, targeting major jurisdictions.
- The patent landscape features several overlapping patents, indicating competitive development within the same chemical class and indication.
- The patent is enforceable until 2032, with broad protection likely to influence market exclusivity.
FAQs
1. Does this patent protect the therapeutic method only in Australia?
No, the patent covers the method within Australia and is part of a broader patent family, with corresponding claims in other jurisdictions.
2. Can competitors develop similar compounds not covered by the claims?
Yes, if they design around the specific structural limitations or use different chemical modifications, they may avoid infringement.
3. What kind of legal challenges could threaten this patent?
Potential challenges include invalidity procedures based on prior art, lack of inventive step, or non-compliance with patentability criteria.
4. How does the patent’s scope compare to similar patents?
It is similar in scope to patents in the same class, focusing on specific chemical structures and use cases, but it may be broader or narrower depending on claim language.
5. Are there existing polymer or formulation patents that could impact this patent’s commercial use?
Likely, yes. Commercial success depends on concurrent rights on formulations, salts, and polymorphs, which are common in pharmaceutical patents.
References
- Australian Patent AU2011264220. (2012). Patent document.
- European Patent Office (EPO). Patent family records, 2012.
- United States Patent and Trademark Office (USPTO). Patent filings related to therapeutic compounds, 2010-2012.
- World Intellectual Property Organization (WIPO). Patent landscape reports, 2021.
